Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Anti-aggregantia- ASA<br />
Gami P. Secondary prevention of ischaemic cardiac events. Clinical Evidence 2007.<br />
Design N/n Population Sd Interventions Outcomes Results<br />
MA (search<br />
1997)<br />
N=195,<br />
n>140.0<br />
00<br />
-High<br />
cardiovascular<br />
risk (evidence<br />
of pre-existing<br />
disease)<br />
1 to<br />
29<br />
m<br />
-Antiplatelet (aspirin<br />
in most cases)<br />
-No antiplatelet<br />
treatment (including<br />
placebo)<br />
Serious vascular<br />
events (MI, stroke,<br />
cv death)<br />
OR=0.77 (95%CI 0.73 to 0.81) in<br />
favour of ASA<br />
- Post MI: NNT/2j 28 (ARR<br />
36/1000/2j)<br />
-Andere hoogrisicopatiënten: NNT/2j =<br />
45/2 (ARR 22/1000/2 j)<br />
N=1,<br />
n=2920<br />
-Subanalysis of<br />
patients with<br />
stable angina,<br />
no previous MI<br />
50<br />
m<br />
-Aspirin 75 mg<br />
-Placebo<br />
n=3197 -Aspirin 500-1500 mg<br />
-Aspirin 75-325 mg<br />
n=3570 -Aspirin >75 mg<br />
-Aspirin
Change language